|
|
 |
Registry of Lobbyists - Christian Kindundu
To find further information on a company or organization check the Registry of Joint Stock Companies
|
|
| Registration Number | Status | | | 1270 | Terminated | | | Initial registration date | Last date of any changes | | 9-October-2014 | 22-September-2015 |
|
Lobbyist's Last Name
Kindundu |
Lobbyist's First Name
Christian |
Middle Initial
|
|
Business Address of Lobbyist
1000 de la Gauchetiere West, suite 500 |
City
Montreal |
Province/State
PQ |
Country
CA |
Postal/Zip Code
H3B 4W5 |
Telephone
514-940-7719 |
Fax
514-844-5495 |
| |
Business or Firm Name for Lobbyist (if applicable)
Lundbeck Canada Inc. |
Registry of Joint Stock Companies Number
|
Business Address of Lobbyist's Business or Firm
1000 de la Gauchetiere West, suite 500 |
City
Montreal |
Province/State
PQ |
Country
CA |
Postal/Zip Code
H3B 4W5 |
Telephone
514-940-7719 |
Fax
514-844-5495 |
|
| Beneficiary Name |
Beneficiary Type |
|
| H. Lundbeck A/S |
Parent Company |
View
|
|
|
|
|
Description of Employer's Business:
Lundbeck Canada Inc. develops, manufactures and/or sells innovative biopharmaceutical medicines for the treatment of disorders originating in the central nervous system (CNS) and for the treatment of cancer. Lundbeck Canada is a wholly-owned subsidiary of H. Lundbeck A/S, a publicly-traded company in Denmark with shareholders. |
| |
|
|
|
| Description |
|
| Focus on ensuring changes to biopharmaceutical legislation & related policies and programs reflect innovative research & development policies, and recognize the value of Lundbeck’s contribution to the Nova Scotia health and life sciences sector economies. Focus on ensuring biopharmaceutical and related legislation, regulations, policies and programs support appropriate reimbursement of biopharmaceuticals by payers and improved patient access to new treatments. Encourage policy and program development and/or modifications that support Lundbeck’s value of medicines positions for the effective management of various mental health conditions and other disabling central nervous system disorders, and for the treatment and management of cancer. |
View
|
|
|
|
|
|
No funding from any government or agency
|
|
No private funding related to lobbying activities
|
|
|
|
|
